Webinar for Authors, Reviewers and Editors

 

Bentham Science and Diffusion Editing present series of webinars for authors, editors and reviewers associated with scientific research.

The series commences with the following webinar.

★WORKING FROM HOME★

May 21st, 2020

Register for Free!

Register for the webinar here: https://bit.ly/2WUtVx9

Testimonial by André Luis Souza dos Santos

Read what our Authors have to say about publishing in our Journal

 

Journal Name: Current Topics Medicinal Chemistry

Contributed Article: EDITORIAL: Old Drugs × New Perspectives/New Compounds × Old Necessities: Focusing on Combating Microbial Resistance – Part II

Testimonial By Sinan Suzen

Read what our Authors have to say about publishing in our Journal

Journal Name: Current Drug Metabolism

Contributed Article:  Volatile Inhibitors of Phosphatidylinositol-3-Kinase (PI3K) Pathway: Anticancer Potential of Aroma Compounds of Plant Essential Oils

Testimonial By Rebecca Pratiti

Read what our Authors have to say about publishing in our Journal

Journal Name: Cardiovascular & Hematological Agents in Medicinal Chemistry

Contributed Article:  Epidemiology And Adverse Consequences Of Hookah/Waterpipe Use: A Systematic Review

Testimonial By Nasim Sarrami

Read what our Authors have to say about publishing in our Journal

 

Journal Name: Anti-Cancer Agents In Medicinal Chemistry

Contributed Article:  LHRH Targeted Chonderosomes Of Mitomycin C In Breast Cancer: An In Vitro/ In Vivo Study

Editors Choice Article | New Folate-Modified Human Serum Albumin Conjugated to Cationic Lipid Carriers for Dual Targeting of Mitoxantrone against Breast Cancer

 

Journal Name: Current Pharmaceutical Biotechnology

Author(s): Abbas A. Ridha,  Soheila Kashanian*, Abbas H. Azandaryani, Ronak Rafipour, Elahe Mahdavian.

 

 

Graphical Abstract:

 

 

Abstract:

Aims: In the present work, folic acid-modified human serum albumin conjugated to cationic solid lipid nanoparticles were synthesized as nanocarriers of mitoxantrone for the treatment of breast cancer.

Background: Dual-targeted drug delivery is a new drug dosing strategy that is frequently used to enhance the therapeutic efficacy of anticancer drugs.

Objective: Dual targeting of the cancer cells was achieved by dual tagging of human serum albumin and folic acid on the surface of the lipid nanoparticles.

Methods: The targeted drug-loaded nanocomplexes were synthesized and characterized using transmission electron microscopy along with photon-correlation and Fourier-transform infrared spectroscopic techniques. The anti-cancer activity of the nanocomplexes was screened against an in-vitro model of MCF-7 and MDA-MB-231 breast cancer cell lines to examine drug efficacy.

Results: The entrapment efficiency and drug loading values for mitoxantrone were calculated to be 97 and 8.84%, respectively. The data from the drug release studies for the system indicated the release profile did not significantly change within a pH range of 5.5-7.4. The hemolysis ratio of the hybrid carrier was less than 5% even at the upper doses of 3 mg/mL, demonstrating its safety for intravenous injection with limited hemolysis and a long blood circulation time.

Conclusion: The cell cytotoxicity results confirmed that the drug hybrid nanocomplex was more toxic to breast cancer cells compared with the free drug. Furthermore, the weakly cationic and small size particles prevented opsonin binding of nanocomplexes, improving blood circulation time and cancer tissue uptake. To read out more, please visit: http://www.eurekaselect.com/node/176690

Testimonial By Ratish Mishra

Read what our Authors have to say about publishing in our Journal

Journal Name: Current Enzyme Inhibition

Contributed Article: Exploring Molecular Docking Studies Of Alanine Racemase Inhibitors From Elettaria Cardamomum

Testimonial By Dr. Jiajia Li

Read what our Authors have to say about publishing in our Journal

 

Journal Name: Current Drug Metabolism

Contributed Article: Interaction between Traditional Chinese Medicine and Anticoagulant/Antiplatelet Drugs

Testimonial By Dr. Bo-Shen Gong

Read what our Authors have to say about publishing in our Journal

Journal Name: Current Cancer Drug Targets

Contributed Article: Nanotherapy Targeting the Tumor Microenvironment

Testimonial | Read what our Authors have to say about publishing in our Journal – By Dr. Sherien M. El-Daly

 

 

Journal Name: Anti-Cancer Agents In Medicinal Chemistry

 

Contributed Article: Synergistic Effect of Α-Solanine and Cisplatin Induces Apoptosis and Enhances Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells